<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Infect Dis Rep</journal-id><journal-id journal-id-type="iso-abbrev">Infect Dis Rep</journal-id><journal-id journal-id-type="publisher-id">idr</journal-id><journal-title-group><journal-title>Infectious Disease Reports</journal-title></journal-title-group><issn pub-type="ppub">2036-7430</issn><issn pub-type="epub">2036-7449</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40407651</article-id><article-id pub-id-type="pmc">PMC12101265</article-id>
<article-id pub-id-type="doi">10.3390/idr17030049</article-id><article-id pub-id-type="publisher-id">idr-17-00049</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Microbiological Surveillance and Antimicrobial Susceptibility Observations on Peritoneal Dialysis-Associated Peritonitis in an Outpatient German Reference Center</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5611-1506</contrib-id><name><surname>Albert</surname><given-names>Annemarie</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-idr-17-00049" ref-type="aff">1</xref><xref rid="af2-idr-17-00049" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Richter</surname><given-names>Stefan</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-idr-17-00049" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6534-1629</contrib-id><name><surname>Costello-Boerrigter</surname><given-names>Lisa C.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af3-idr-17-00049" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6103-9038</contrib-id><name><surname>Stieger</surname><given-names>Philipp</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af4-idr-17-00049" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Woitas</surname><given-names>Rainer Peter</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af1-idr-17-00049" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3888-6532</contrib-id><name><surname>Braun-Dullaeus</surname><given-names>R&#x000fc;diger C.</given-names></name><xref rid="af4-idr-17-00049" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6956-9962</contrib-id><name><surname>Albert</surname><given-names>Christian</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="af1-idr-17-00049" ref-type="aff">1</xref><xref rid="af2-idr-17-00049" ref-type="aff">2</xref><xref rid="af4-idr-17-00049" ref-type="aff">4</xref><xref rid="c1-idr-17-00049" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Goldenberg</surname><given-names>Simon D.</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-idr-17-00049"><label>1</label>Diaverum Renal Services, Am Neuen Garten 11, 14469 Potsdam, Germany<email>rainer.woitas@diaverum.com</email> (R.P.W.)</aff><aff id="af2-idr-17-00049"><label>2</label>Department of Nephrology, Central Clinic Bad Berka, Robert-Koch-Allee 9, 99438 Bad Berka, Germany</aff><aff id="af3-idr-17-00049"><label>3</label>Department of Cardiology and Intensive Care Medicine, Central Clinic Bad Berka, Robert-Koch-Allee 9, 99438 Bad Berka, Germany</aff><aff id="af4-idr-17-00049"><label>4</label>University Clinic for Cardiology and Angiology, Otto-von-Guericke University Magdeburg, Leipziger Str. 44, 39120 Magdeburg, Germany</aff><author-notes><corresp id="c1-idr-17-00049"><label>*</label>Correspondence: <email>christian.albert@med.ovgu.de</email></corresp></author-notes><pub-date pub-type="epub"><day>03</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2025</year></pub-date><volume>17</volume><issue>3</issue><elocation-id>49</elocation-id><history><date date-type="received"><day>18</day><month>2</month><year>2025</year></date><date date-type="rev-recd"><day>25</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>30</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><bold>Background</bold>: Peritonitis is a relevant complication in peritoneal dialysis (PD). The initial empirical antibiotic therapy depends on the center-specific distribution of microorganisms and the microbial susceptibility profiles. However, data on the locoregional germ spectrum in Germany are insufficient regarding the current recommended empirical antibiotic regimens of either cefepime as monotherapy or the combination of cefazolin and ceftazidime. <bold>Methods</bold>: This retrospective single-center study of routine clinical patient data analyzes the range of infecting organisms causing PD-associated peritonitis and their corresponding antimicrobial resistances during the 2015 to 2022 timeframe. We used Ordinary Least-Squares regression to model trends in the detection of microbiological spectrum samples. The &#x02018;reporting of studies conducted using observational routinely collected health data&#x02019; (RECORD) statement was acknowledged. <bold>Results</bold>: There were 80 documented peritonitis episodes with 99 causal etiologies sampled. Of those, eighty-seven were bacterial, three were fungi (3%), eight had no microbial growth (8%), and one more had missing data. The largest group of microorganisms detected were Gram-positive bacteria (N = 56, 56.6%), predominantly sampled as Staphylococcacea, Enterococcaceae, and Streptococcaceae (<italic toggle="yes">Staphylococcus aureus</italic>, 14.1%). Gram-negative bacteria were found in 31.3% of samples (N = 31), predominantly Enterobacteriaceae (<italic toggle="yes">Escherichia coli</italic>, 9%). In total, 34 different microorganisms were identified. On one occasion, methicillin-resistant <italic toggle="yes">Staphylococcus epidermidis</italic> and one sample of multi-resistant <italic toggle="yes">Serratia marcescens</italic> were identified. Methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic> and vancomycin-resistant enterococci were not detected. Fungi were found in three peritonitis episodes. Regression analyses did not indicate changes in the general microbiological spectrum during the observational timeframe. The center-specific peritonitis rates were below the recommended rates of the International Society for Peritoneal Dialysis for all years studied. <bold>Conclusions</bold>: The recommended empiric therapy was suitable at our center, with a few exceptions for non-specific pathogens and for those with &#x003b2;-lactamases or enterococci. When there is no clinical response to empiric therapy, alternative antibiotics should be considered accordingly. The retrospective data are limited to the reported outcome measures.</p></abstract><kwd-group><kwd>peritoneal dialysis</kwd><kwd>peritonitis</kwd><kwd>Gram-negative organisms</kwd><kwd>Gram-positive organisms</kwd><kwd>antibiotic stewardship</kwd><kwd>antibiotics</kwd><kwd>renal replacement therapy</kwd><kwd>pathogen spectrum</kwd></kwd-group><funding-group><award-group><funding-source>Open Access Publication Fund of Magdeburg University</funding-source></award-group><funding-statement>This research was supported by the Open Access Publication Fund of Magdeburg University.</funding-statement></funding-group></article-meta></front><body><sec id="sec1-idr-17-00049"><title>1. Background</title><p>Peritoneal dialysis (PD) is a widely used renal replacement therapy that allows end-stage renal disease patients to have home-based treatment [<xref rid="B1-idr-17-00049" ref-type="bibr">1</xref>]. However, persons undergoing PD independently at home are occasionally faced with relevant medical or procedural complications [<xref rid="B2-idr-17-00049" ref-type="bibr">2</xref>]. Specifically, the connect and disconnect procedures are associated with the risk of contamination with subsequent development of PD-associated peritonitis [<xref rid="B3-idr-17-00049" ref-type="bibr">3</xref>].</p><p>Excluding pre-PD peritonitis and PD catheter insertion-related peritonitis, the risk of PD-associated peritonitis is 0.26&#x02013;0.40 episodes per patient per year (peritonitis rate) worldwide [<xref rid="B4-idr-17-00049" ref-type="bibr">4</xref>]. To increase further the adoption of PD in an ambulatory center, it is therefore mandatory to address this complication adequately. The 2022 guidelines from the International Society for Peritoneal Dialysis (ISPD) recommend that dialysis programs monitor yearly peritonitis rates with a goal peritonitis rate of 0.40 or less [<xref rid="B4-idr-17-00049" ref-type="bibr">4</xref>]. It is likewise recommended that organism-specific peritonitis rates, antimicrobial susceptibilities, and culture-negative peritonitis all be monitored and reported [<xref rid="B4-idr-17-00049" ref-type="bibr">4</xref>]. In general, PD-associated peritonitis can be successfully treated with appropriate intraperitoneal (IP) antibiotics.</p><p>However, currently knowledge of the locoregional microbiological spectrum in Germany is insufficient. Therefore, in keeping with the ISPD recommendations and guiding the implementation of an antibiotic stewardship program to improve empirical therapy and to monitor our center&#x02019;s resistance rates in PD-associated peritonitis [<xref rid="B5-idr-17-00049" ref-type="bibr">5</xref>], we report for the first time the range of infecting organisms causing PD-associated peritonitis and their corresponding antimicrobial resistances in our representative PD cohort from northeastern Germany.</p></sec><sec id="sec2-idr-17-00049"><title>2. Materials and Methods</title><sec id="sec2dot1-idr-17-00049"><title>2.1. Data Collection</title><p>Clinical data were retrospectively collected from patients undergoing PD at the Diaverum reference center in Potsdam, Germany. The data covered the time period from 1 January 2015 to 31 December 2022 and included patient numbers and characteristics, PD dates, PD modality, peritonitis date, causative microorganisms, bacterial sampling, antibiotic sensitivity testing for medication(s) used. Additional yearly data, such as total delivered PD treatment days and total number of patients, were extracted to calculate the center-specific peritonitis rate.</p></sec><sec id="sec2dot2-idr-17-00049"><title>2.2. Diagnosis</title><p>PD-associated peritonitis was defined according to the ISPD 2022 guidelines, which require the presence of two of the following three findings: clinical features consistent with peritonitis (e.g., abdominal pain, cloudy dialysis effluent), dialysis effluent white blood cell (WBC) count &#x0003e; 100/&#x000b5;L or &#x0003e;0.1 &#x000d7; 10<sup>9</sup>/L (after a dwell time of at least 2 h) with &#x0003e;50% polymorphonuclear leukocytes (PMN), and/or a positive dialysis effluent culture [<xref rid="B4-idr-17-00049" ref-type="bibr">4</xref>].</p><p>The definition of a medical cure was likewise based upon ISPD 2022 guidelines and consisted of the complete resolution of peritonitis and no relapse, recurrent peritonitis, catheter removal, transfer to hemodialysis for &#x02265;30 days, or death [<xref rid="B4-idr-17-00049" ref-type="bibr">4</xref>].</p></sec><sec id="sec2dot3-idr-17-00049"><title>2.3. Standardized Sample Handling</title><p>Under sterile conditions, a volume of 20 mL dialysate was collected and placed in a pair of aerobic and anaerobic blood culture bottles for testing. If patients presented to our center with a dry cavity, then according to ISPD recommendations, a dwell for one hour was performed before using the drained dialysate for analysis. If the patient noticed cloudy dialysate from the prior night&#x02019;s dwell, then the patient was instructed to bring the night bag to our center for diagnostics.</p><p>All samples were collected twice daily from our center by our associated service partner Labor 28 (Berlin, Germany), which specializes in laboratory medicine and microbiology. Gram staining was performed according to protocol. All cultures were grown, tested, and analyzed for antimicrobial sensitivities by Labor 28 (Berlin, Germany) according to the respective manufacturer&#x02019;s recommendations. Blood culture bottles (BACTEC) were used from BD (Becton Dickinson and Company, Heidelberg, Germany) and were routinely incubated for seven days. Bacterial identification was performed using the MALDI Biotyper System (Bruker Corporation, Billerica, MA, USA).</p></sec><sec id="sec2dot4-idr-17-00049"><title>2.4. Evaluation of Microbial Spectrum and Resistance Profile</title><p>To determine the microbial spectrum for the region, all causative microorganisms were recorded and grouped according to species, microbiological staining behavior (Gram stain), and morphology. It was also recorded if no microorganism could be identified (culture-negative peritonitis) or if patient data were missing.</p><p>To analyze the resistance profiles, the causative organisms were classified according to three main groups (Gram-positive, Gram-negative, and fungi) and, when possible, according to family and species type. Multi-resistant pathogens were reported separately.</p></sec><sec id="sec2dot5-idr-17-00049"><title>2.5. Treatment Regimens</title><p>At the Diaverum dialysis center, antibiotic treatment was performed IP at initial patient presentation and continued daily in the long interval exchange using an icodextrin solution (Baxter, BX, Unterschlei&#x000df;heim, Germany) with a dwell time of at least six hours. Cefazolin and ceftazidime were administered as the daily empirical antibiotic therapy until 2019. Since January 2019, cefepime was used as monotherapy. Both selections are consistent with the ISPD&#x02019;s 2022 guidelines, which suggest the use of a first-generation cephalosporin or vancomycin to cover Gram-positive organisms and a third-generation cephalosporin or an aminoglycoside to cover Gram negatives or, alternatively, cefepime monotherapy [<xref rid="B4-idr-17-00049" ref-type="bibr">4</xref>]. The antibiotic regimen was then refined after identification of the causative organism(s) and their respective antimicrobial resistances. The duration of therapy was dependent upon the pathogen.</p><p>Given that additional antibiotic regimens were available at the Diaverum center and their collaborating hospitals, those antibiotics were also included in the summary resistance analysis where reasonable and where the data were available.</p></sec><sec id="sec2dot6-idr-17-00049"><title>2.6. Ethical Approval</title><p>This retrospective analysis of routinely collected clinical patient record data was part of an internal quality improvement program. Given the retrolective nature of this investigation, necessity for patient consent to participate was exempt by the institutional review board of Diaverum Germany in accordance with German legal requirements (&#x000a7; 27 BDSG, Bundesdatenschutzgesetz) enabling anonymized &#x02018;data processing for scientific or historical research purposes&#x02019;. The study protocol was in concordance with the ethical guidelines of the Declaration of Helsinki and was approved by both the Institutional Review Board of Diaverum and the Otto-von-Guericke University Medical Faculty Ethics Committee, Magdeburg, Germany, Case No. 142/22 (approved on 21 November 2022).</p></sec><sec id="sec2dot7-idr-17-00049"><title>2.7. Analysis</title><p>The center-specific peritonitis rate (PR) was calculated using Formula (1) for all years of the study period [<xref rid="B6-idr-17-00049" ref-type="bibr">6</xref>].<disp-formula id="FD1-idr-17-00049"><label>(1)</label><mml:math id="mm1" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mi>R</mml:mi><mml:mo>=</mml:mo><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac bevelled="true"><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:msub><mml:mrow><mml:mi>S</mml:mi><mml:mi>u</mml:mi><mml:mi>m</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>o</mml:mi><mml:mi>f</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>P</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mi>i</mml:mi><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mi>i</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>E</mml:mi><mml:mi>p</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mi>o</mml:mi><mml:mi>d</mml:mi><mml:mi>e</mml:mi><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mi>y</mml:mi><mml:mi>e</mml:mi><mml:mi>a</mml:mi><mml:mi>r</mml:mi></mml:mrow></mml:msub><mml:mtext>&#x000a0;</mml:mtext></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mi>f</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>N</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>P</mml:mi><mml:mi>t</mml:mi><mml:mi>s</mml:mi><mml:mo>.</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow><mml:mrow><mml:mrow><mml:msubsup><mml:mo stretchy="true">&#x02211;</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>P</mml:mi><mml:mi>t</mml:mi><mml:mo>.</mml:mo></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>P</mml:mi><mml:mi>t</mml:mi><mml:mo>.</mml:mo></mml:mrow><mml:mrow><mml:mi>N</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msubsup><mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:mfrac><mml:mrow><mml:mrow><mml:mo stretchy="false">&#x02211;</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>P</mml:mi><mml:mi>D</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>d</mml:mi><mml:mi>a</mml:mi><mml:mi>y</mml:mi><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mi>y</mml:mi><mml:mi>e</mml:mi><mml:mi>a</mml:mi><mml:mi>r</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:mrow><mml:mrow><mml:mn>365.25</mml:mn></mml:mrow></mml:mfrac></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:mrow></mml:mfrac></mml:mstyle></mml:mrow></mml:mrow></mml:math></disp-formula></p><p>The conduction of the study conformed to the &#x02018;reporting of studies conducted using observational routinely collected health data&#x02019; (RECORD) statement [<xref rid="B7-idr-17-00049" ref-type="bibr">7</xref>].</p><p>We used two methods to estimate temporal trends in the detection of microbiological spectrum samples. First, we applied Locally Estimated Scatterplot Smoothing (LOESS) to provide an estimate representation of non-linear detection rate trends over time by fitting local polynomial regressions to subsets of the data. To illustrate the uncertainty around the smoothed curves, the associated confidence areas were computed using standard error estimates from the LOESS fit.</p><p>As a secondary approach, an Ordinary Least-Squares (OLS) regression model was applied separately for each category of microorganisms. The detection rate was modeled as a function of time (years, 2015 to 2022), where the slope coefficient (&#x003b2;1) indicated the direction of the trend. To determine the statistical significance of these trends, a <italic toggle="yes">p</italic>-value was obtained from the regression model and considered significant when below 0.05. We calculated the 95% confidence intervals for the linear regression using the standard error of the estimated regression coefficients.</p><p>All statistical analyses and illustrations were performed using the R environment for statistical computing (R Foundation for Statistical Computing, Vienna, Austria) [<xref rid="B8-idr-17-00049" ref-type="bibr">8</xref>] with the <italic toggle="yes">mass</italic> package version 7.3-64 [<xref rid="B9-idr-17-00049" ref-type="bibr">9</xref>].</p></sec></sec><sec sec-type="results" id="sec3-idr-17-00049"><title>3. Results</title><sec id="sec3dot1-idr-17-00049"><title>3.1. Demographic and Clinical Characteristics</title><p>From 1 January 2015 to 31 December 2022, the dialysis practice being evaluated cared for 129 patients who were undergoing or initiating PD. The most frequent PD procedure performed was automated PD (APD) for 79 patients. Continuous ambulatory PD (CAPD) was performed in 39 patients and intermittent PD (IPD) in 11 patients. The median time from PD initiation to first peritonitis episode was 13 months (<xref rid="idr-17-00049-t001" ref-type="table">Table 1</xref>).</p></sec><sec id="sec3dot2-idr-17-00049"><title>3.2. Distribution of Peritonitis Episodes</title><p>Forty-six patients (35.66%) were affected by at least one episode of peritonitis, with a total of 80 episodes occurring in the observational timeframe, while 83 (64.34%) had no peritonitis episodes.</p><p>The number of patients receiving PD increased over time, from 36 in 2015 to 51 in 2022, with a peak of 58 in 2020. The number of peritonitis episodes likewise peaked in 2020 (N = 14); however, despite the increase in patients from the beginning to the end of the period, the relative number of peritonitis episodes as calculated by the center-specific peritonitis rate declined from 2015 to 2022 as shown in <xref rid="idr-17-00049-f001" ref-type="fig">Figure 1</xref>.</p></sec><sec id="sec3dot3-idr-17-00049"><title>3.3. Spectrum of Causative Bacteria</title><p>In total, we detected 87 bacterial microorganisms. The largest group of microorganisms detected were Gram-positive bacteria (N = 56), followed by Gram-negative bacteria (N = 31). Fungi (<italic toggle="yes">Candida</italic> spp.) formed the smallest etiological group being detected in three peritonitis episodes. In total, 34 different microorganism were identified (<xref rid="idr-17-00049-t002" ref-type="table">Table 2</xref>, <xref rid="app1-idr-17-00049" ref-type="app">Supplementary Figure S1</xref>). <italic toggle="yes">Staphylococcus</italic> spp., predominantly <italic toggle="yes">Staphylococcus aureus</italic> and <italic toggle="yes">Streptococcus</italic> spp. were the most commonly identified Gram-positive bacteria. In the Gram-negative spectrum, <italic toggle="yes">Escherichia coli</italic> and <italic toggle="yes">Enterobacter cloacae</italic> were the most frequently detected pathogens. Other organisms identified were all fungi from the <italic toggle="yes">Candida</italic> spp.</p><p>The ISPD guidelines recommend that the methods used for sampling and incubation be reviewed if microbial growth is not possible in more than 15% of cases [<xref rid="B4-idr-17-00049" ref-type="bibr">4</xref>]. Overall, there were culture-negative samples on eight occasions during the period under review (8.08%). However, on a per year basis, the number of culture-negative tests exceeded the ISPD recommendation in 2018 at 23.1% (N = 3). One peritonitis episode had missing data (<xref rid="idr-17-00049-f002" ref-type="fig">Figure 2</xref>).</p></sec><sec id="sec3dot4-idr-17-00049"><title>3.4. Changes in the Pathogenic Spectrum over Time</title><p>Gram-positive bacteria were the most common pathogenic organisms every year, except for 2018 and 2022, when Gram-negative bacteria surpassed them. The difference between Gram-positive and Gram-negative pathogens was greatest in 2021, although the numbers were small (<xref rid="app1-idr-17-00049" ref-type="app">Supplementary Table S1</xref>).</p><p>Fungi were only identified in three years (2015, 2018, and 2020), with only one detection in each of those years (<xref rid="idr-17-00049-f002" ref-type="fig">Figure 2</xref>). There were multiple episodes with sampling of multiple organisms. Both were associated with at least temporal peritonitis associated modality switch to hemodialysis (<xref rid="app1-idr-17-00049" ref-type="app">Supplementary Table S2</xref>).</p><p>However, in the observational timeframe, there were no significant trends regarding the sampling of Gram-negative (<italic toggle="yes">p</italic> = 0.326) or Gram-positive (<italic toggle="yes">p</italic> = 0.252) pathogens, fungi (<italic toggle="yes">p</italic> = 0.465), or frequency of culture-negative samples (<italic toggle="yes">p</italic> = 0.159) (<xref rid="idr-17-00049-f003" ref-type="fig">Figure 3</xref>a,b, <xref rid="app1-idr-17-00049" ref-type="app">Supplementary Figure S2</xref>).</p><p>In <xref rid="app1-idr-17-00049" ref-type="app">Supplemental Figure S3</xref>, we explored the hypothesis that the higher Gram-negative count, as opposed to the expected Gram-positive count seen in <xref rid="idr-17-00049-f002" ref-type="fig">Figure 2</xref> in the last study year, might be an outlier phenomenon and excluded the year 2022 from the data assessment. Following this hypothesis, and excluding the 2022 data, there was no indication of an increase in Gram-negative bacteria (<italic toggle="yes">p</italic> = 0.485) and an almost horizontal trend line for the Gram-positive bacteria (<italic toggle="yes">p</italic> = 0.913).</p></sec><sec id="sec3dot5-idr-17-00049"><title>3.5. Resistance Profiles</title><p>The available sensitivity testing results for Gram-positive and Gram-negative bacteria, respectively, are summarized in <xref rid="idr-17-00049-t003" ref-type="table">Table 3</xref>. Out of 90 differentiated microorganisms, there were 29 resistance profiles missing (of 22 individual peritonitis episodes). <italic toggle="yes">Staphylococcus aureus</italic>, one of the four most commonly detected Gram-positive bacteria were found to be completely sensitive to the primary antibiotics recommended by the Paul Ehrlich Society guidelines for intravenous therapy of PD-associated peritonitis [<xref rid="B10-idr-17-00049" ref-type="bibr">10</xref>], namely cefazoline, cefuroxime, ceftriaxone, ceftazidime, and ciprofloxacin. The <italic toggle="yes">Streptococcus</italic> spp. behaved similarly, with the exception of resistance to ciprofloxacin.</p><p>The present analysis primarily focused on antibiotics outlined in the ISPD guidelines for IP treatment, in particular cefazolin, cefepime, vancomycin, and gentamicin. <italic toggle="yes">Staphylococcus aureus</italic>, <italic toggle="yes">Strepotococcus</italic> spp., and <italic toggle="yes">Enterococcus</italic> spp. only showed resistance to gentamicin. <italic toggle="yes">Staphylococcus epidermidis</italic>, on the other hand, demonstrated resistance to cefazolin and cefepime. Additionally, oxacillin resistance was noted in four other Gram-positive samples of <italic toggle="yes">Staphylococcus epidermidis</italic>, <italic toggle="yes">Streptococcus salivarius</italic>, <italic toggle="yes">Staphylococcus hominis</italic>, and <italic toggle="yes">Listeria monozytogenes</italic>. <italic toggle="yes">Enterococcus</italic> spp. showed the highest distribution of resistance to all cephalosporin antibiotics tested, which was expected given their known intrinsic resistance to antibiotics that are directed against the bacterial cell wall [<xref rid="B11-idr-17-00049" ref-type="bibr">11</xref>]. Ciprofloxacin was the only Paul Ehrlich Society recommended antibiotic to which these species were not resistant.</p><p>In the group of Gram-negative bacteria, <italic toggle="yes">Enterobacter cloacae</italic>, and <italic toggle="yes">Klebsiella</italic> spp. were sensitive to the primary, recommended antibiotics. <italic toggle="yes">Escherichia coli</italic> was only consistently sensitive to cetriaxone. Yet, the Gram-negative group of pathogens showed full sensitivity to the ISPD antibiotics tested.</p><p>Other antibiotics analyzed for sensitivity were linezolid, which is used as a reserve antibiotic for Gram-positive bacteria, penicillin G for streptococcal infections, ampicillin/sulbactam, and piperacillin/tazobactam for an extended spectrum of activity against Gram-positive and Gram-negative bacteria, and imipenem and piperacillin/tazobactam against <italic toggle="yes">Pseudomonas aeruginosa</italic>. Gram-positive pathogens showed full sensitivity to linezolid and streptococci to penicillin G. <italic toggle="yes">Staphylococcus epidermidis</italic> and <italic toggle="yes">Enterococcus</italic> spp. showed resistance to ampicillin/sulbactam, piperacillin/tazobactam, and imipenem. In the group of Gram-negative pathogens, a sensitivity to the same antibiotics was observed with only ampicillin/sulbactam standing out as an exception.</p></sec><sec id="sec3dot6-idr-17-00049"><title>3.6. Multi-Drug-Resistant and Atypical Pathogens</title><p>In the group of staphylococcaceae, we found resistance to penicillin G and ampicillin, which is rather expected; however, one sample identified <italic toggle="yes">Staphylococcus epidermidis</italic> was resistant to oxacillin fulfilling MRSE criteria. Methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic> (MRSA) and vancomycin-resistant enterococci (VRE) were not detected. Multi-resistant Gram-negative pathogens (MRGN) were detected in one sample of <italic toggle="yes">Serratia marcescens</italic> that was resistant to four classes of Gram-negative-active antibiotics (<italic toggle="yes">4MRGN</italic>) (<xref rid="idr-17-00049-t003" ref-type="table">Table 3</xref>). There were no 3MRGN sampled.</p><p>The sampled <italic toggle="yes">Candida</italic> spp. were sensitive to all major antifungal medication (amphotericin, caspofungin, fluconazol, micafungin, and voriconazol).</p><table-wrap position="anchor" id="idr-17-00049-t003"><object-id pub-id-type="pii">idr-17-00049-t003_Table 3</object-id><label>Table 3</label><caption><p>In vitro susceptibility rates of selected Gram-positive and Gram-negative pathogens with N &#x0003e; 2 identified samples.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Antibiotics</th><th colspan="9" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Microorganisms [s (r)]</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Staphylococcus aureus</italic>
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Staphylococcus epidemidis</italic>
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Streptococcus</italic> spp.</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Enterococcus</italic> spp.</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Enterobacter cloacae</italic>
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Escherichia coli</italic>
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Klebsiella</italic> spp.</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Serratia marcescens</italic>
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Acinetobacter</italic> spp.</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Penicillines</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Penicillin G</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (2)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (3)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">NT</td><td align="center" valign="middle" rowspan="1" colspan="1">NT</td><td align="center" valign="middle" rowspan="1" colspan="1">NT</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (2)</td><td align="center" valign="middle" rowspan="1" colspan="1">NT</td><td align="center" valign="middle" rowspan="1" colspan="1">NT</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Ampicillin</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (3)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (3)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (1)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (1)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (5)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (1)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (2)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (2)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Ampicillin/Sulbactam</td><td align="center" valign="middle" rowspan="1" colspan="1">9 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (1)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (1)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (1)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (3)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (1)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Piperacillin/Tazobactam</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (1)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (1)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (1)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Oxacillin</td><td align="center" valign="middle" rowspan="1" colspan="1">9 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (1)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (1)</td><td align="center" valign="middle" rowspan="1" colspan="1">NT</td><td align="center" valign="middle" rowspan="1" colspan="1">NT</td><td align="center" valign="middle" rowspan="1" colspan="1">NT</td><td align="center" valign="middle" rowspan="1" colspan="1">NT</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (1)</td><td align="center" valign="middle" rowspan="1" colspan="1">NT</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Cephalosporines</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Cefazolin (1) <sup>1</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">4 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (1)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">NT</td><td align="center" valign="middle" rowspan="1" colspan="1">NT</td><td align="center" valign="middle" rowspan="1" colspan="1">NT</td><td align="center" valign="middle" rowspan="1" colspan="1">NT</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (1)</td><td align="center" valign="middle" rowspan="1" colspan="1">NT</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Cefuroxim (2) <sup>1</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">11 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (1)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (2)</td><td align="center" valign="middle" rowspan="1" colspan="1">NT</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (2)</td><td align="center" valign="middle" rowspan="1" colspan="1">NT</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (1)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Ceftriaxon (3a) <sup>1</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">5 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (1)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (2)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (1)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (1)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Ceftazidim (3b) <sup>1</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">2 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (1)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (1)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (1)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (1)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (2)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Cefepim (4) <sup>1</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (1)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">NT</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">NT</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (1)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (1)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Carbapenemes</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Imipinem</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (1)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (1)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (1)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (0)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Meropenem</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (1)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (1)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (1)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (0)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Chinolone</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Ciprofloxacin</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (1)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (1)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (1)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (0)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Levofloxacin</td><td align="center" valign="middle" rowspan="1" colspan="1">10 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (1)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (1)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (0)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Glykopeptides</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Vancomycin</td><td align="center" valign="middle" rowspan="1" colspan="1">9 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">NT</td><td align="center" valign="middle" rowspan="1" colspan="1">NT</td><td align="center" valign="middle" rowspan="1" colspan="1">NT</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">NT</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Aminoglykosides</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Gentamicin</td><td align="center" valign="middle" rowspan="1" colspan="1">11 (1)</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (2)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (1)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (0)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Oxazolidinone</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Linezolid</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">NT</td><td align="center" valign="middle" rowspan="1" colspan="1">NT</td><td align="center" valign="middle" rowspan="1" colspan="1">NT</td><td align="center" valign="middle" rowspan="1" colspan="1">NT</td><td align="center" valign="middle" rowspan="1" colspan="1">NT</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Total (n) <sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td></tr></tbody></table><table-wrap-foot><fn><p>[s (r)] = s, sensitive; r, resistant, spp., species; NT, not tested; <sup>1</sup> Cephalosporine 1st to 4th generation; <sup>2</sup> Number of times that microorganism were identified in all peritonitis episodes; Numbers may not add up as not all microorganisms were tested for all given antibiotics. Detection of multi-drug-resistant specimen: 1&#x000d7; MRSE; 1&#x000d7; 4MRGN Serratia marcescens; MRSA, VRE, or 3MRGN were not detected.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion" id="sec4-idr-17-00049"><title>4. Discussion</title><p>We report here the first systematic analysis of the pathogens and antibiotic resistance patterns identified in peritonitis patients undergoing ambulatory PD from an outpatient German reference center in the federal state of Brandenburg, Germany. Using retrospective, routinely collected patient data from 2015 to 2022, we found that Gram-positive bacteria were identified more frequently than Gram-negative bacteria and that fungal infections were rare, which is consistent with previous observations in other cohorts [<xref rid="B12-idr-17-00049" ref-type="bibr">12</xref>]. We did not see a systematic trends for a change in the microbiological spectrum in the observational timeframe. The bacterial pathogens were adequately sensitive to the ISPD guideline-recommended antibiotics.</p><p>As suggested by the ISPD in 2022, the overall peritonitis rate should be no more than 0.40 (down from 0.5) episodes per year, which was 0.21 for our center in the last year of this study [<xref rid="B4-idr-17-00049" ref-type="bibr">4</xref>]. In our center, we implemented an ongoing quality improvement program for PD, specifically regarding the training and retraining of patients and nurses regarding emerging PD issues and infection prevention [<xref rid="B2-idr-17-00049" ref-type="bibr">2</xref>]. Hence, with increasing patient numbers, the center peritonitis rate was declining, which is generally seen as a reflection of increasing competence and specialization of a PD center [<xref rid="B13-idr-17-00049" ref-type="bibr">13</xref>].</p><p>The finding that Gram-positive organisms, especially <italic toggle="yes">Staphylococcus aureus</italic>, <italic toggle="yes">Staphylococcus epidermis</italic>, and streptococci representing the most common pathogens was in keeping with studies from Stuttgart (Germany) [<xref rid="B12-idr-17-00049" ref-type="bibr">12</xref>], Heraklion (Greece) [<xref rid="B14-idr-17-00049" ref-type="bibr">14</xref>], and Amsterdam (The Netherlands) [<xref rid="B15-idr-17-00049" ref-type="bibr">15</xref>].</p><p>Clinically, most peritonitis is transmitted by touch resembling common skin and mucosal flora from the nasopharynx, and because hygiene protocols such as the non-touch technique, hand disinfection, or the wearing of face masks are not followed sufficiently. It is of interest to note that according to a general consent of outpatient care providers in Germany, our patients are not required to apply daily mupirocin to the exit site.</p><p>We found that in 2022, there was a predominant Gram-negative pathogen sampling in peritonitis. It is unclear if this is an initial indication of a trend change in the bacterial spectrum or an outlier phenomenon, as this year was the last of the study. Due to the ongoing COVID-19 pandemic, the reduction in Gram-positive findings might be secondary to the increased practice of wearing facemasks. In a PD population in Suzhou (China), the proportion of Gram-negative bacteria causing peritonitis increased from 0% to 26.15% over a period of 10 years [<xref rid="B16-idr-17-00049" ref-type="bibr">16</xref>]. Any concern for a trend in this direction should be carefully monitored because PD patients with Gram-negative peritonitis have been found to have lower cure rates, increased severity of symptoms, higher rates of hospitalization, and an increased likelihood to be transferred to hemodialysis [<xref rid="B17-idr-17-00049" ref-type="bibr">17</xref>,<xref rid="B18-idr-17-00049" ref-type="bibr">18</xref>]. Yet, as opposed to Zeng et al. [<xref rid="B16-idr-17-00049" ref-type="bibr">16</xref>], regarding the overall observational timeframe, we did not see systematic changes or trends in the detection rate of microorganism categories.</p><p>Unlike the reports from Stuttgart and Amsterdam, <italic toggle="yes">Pseudomonas aeruginosa</italic> was not found to be causative in any of our cases [<xref rid="B12-idr-17-00049" ref-type="bibr">12</xref>,<xref rid="B15-idr-17-00049" ref-type="bibr">15</xref>]. Furthermore, unlike the situation in Stuttgart, we did not find relevant proportions of bacteria that were resistant to multiple antibiotics, specifically MRSA or VRE or mycobacteria [<xref rid="B12-idr-17-00049" ref-type="bibr">12</xref>]. However, we identified in one case solely a sample of methicillin-resistant <italic toggle="yes">Staphylococcus epidermidis</italic> (MRSE), which was treated using vancomycin. In one sample, we detected a 4MRGN <italic toggle="yes">Serratia marcescens</italic>. Although the local bacterial spectra are comparable between our study and the Stuttgart population in terms of the distribution of the Gram-positive and Gram-negative bacteria, the distribution of the individual species and their resistances are different [<xref rid="B12-idr-17-00049" ref-type="bibr">12</xref>]. This may reflect the difference in patient proportion who are treated as inpatients versus outpatients This hypothesis should be considered in future studies. As in most centers in Europe, the US, and increasingly in other regions, APD was the modality most often used by our PD patients [<xref rid="B19-idr-17-00049" ref-type="bibr">19</xref>]. More than 61% of our PD patients used APD, as opposed to approximately 30% who used CAPD. This is noteworthy because some studies suggest that APD patients have a lower risk of peritonitis since they usually only perform one connect and one disconnect per day. In contrast, CAPD generally use up to four dialysis bags per 24 h period, consequently leading to multiple connecting and disconnecting procedures a day, potentially increasing the risk for contamination [<xref rid="B20-idr-17-00049" ref-type="bibr">20</xref>].</p><p>Peritonitis due to <italic toggle="yes">Candida</italic> spp. is rare. In our cohort, it was found in one patient with immunosuppression, and in one who was treated with antibiotics for prolonged periods suffering from diabetic foot syndrome and osteomyelitis. <italic toggle="yes">Candida</italic> spp. preferentially adheres to the plastic surfaces of catheters and implants and thus leads to nosocomial candidiasis. This was potentially the cause of our center&#x02019;s third fungal peritonitis. This patient had two relapses of <italic toggle="yes">Brevibacterium caseii</italic> peritonitis, and even though thorough investigation was performed, no reservoir could be identified for the bacterium. After two cycles of antibiotic therapy, the patient&#x02019;s condition worsened due to fungal peritonitis, which necessitated removal of the catheter. The patient was able to resume PD with a new PD catheter that was inserted after three months. In patients at risk, prophylactic application of antifungal medication should be considered [<xref rid="B21-idr-17-00049" ref-type="bibr">21</xref>].</p><p>Since 2019, we have usually started the antibiotic therapy with cefepime as opposed to cefazolin and ceftazidime; both regimens are in keeping with the ISPD 2022 guidelines [<xref rid="B4-idr-17-00049" ref-type="bibr">4</xref>]. The antibiotic regimen was then subsequently adjusted as necessary after pathogen identification and resistance assessment [<xref rid="B4-idr-17-00049" ref-type="bibr">4</xref>]. IP administration of cefepime is not inferior to the IP administration of the cefazolin and ceftazidime combination [<xref rid="B22-idr-17-00049" ref-type="bibr">22</xref>]. As a fourth-generation cephalosporin, cefepime is a broad-spectrum antibiotic with activity against both Gram-positive and Gram-negative bacteria, as well as against <italic toggle="yes">Pseudomonas aeruginosa</italic>, which is often resistant to a wide range of antibiotics [<xref rid="B23-idr-17-00049" ref-type="bibr">23</xref>]. IP therapy is recommended, as well as the preferred route of administration [<xref rid="B4-idr-17-00049" ref-type="bibr">4</xref>], and cefazolin, ceftazidime, and cefepime are safe and stable for IP application using icodextrin [<xref rid="B24-idr-17-00049" ref-type="bibr">24</xref>].</p><p>Acquired resistance to cefepime is generally found in multi-resistant bacteria and in <italic toggle="yes">Staphylococcus hominis</italic> or <italic toggle="yes">Staphylococcus haemolyticus</italic>. Some of these pathogens were in the local bacterial spectrum, but an unfavorable range of resistances were not identified. The sampling frequency of <italic toggle="yes">Staphylococcus aureus</italic>, however, bears individual risk of biofilming, irrespective of antibiotic resistance [<xref rid="B25-idr-17-00049" ref-type="bibr">25</xref>].</p><p>Additionally, we recognized the resistance profile of identified <italic toggle="yes">Serratia marcescens</italic> samples that have the ability of to produce extended-spectrum &#x003b2;-lactamases (ESBL) after acquiring the corresponding plasmids [<xref rid="B26-idr-17-00049" ref-type="bibr">26</xref>], and the innate resistance of Enterococcaceae to cephalosporins during antibiotic susceptibility testing. The association of <italic toggle="yes">Enterococcus</italic> spp. with healthcare setting-acquired infections and with a propensity to multi-drug resistance is highly relevant [<xref rid="B11-idr-17-00049" ref-type="bibr">11</xref>]. Specifically, in the event of an initial non-response to treatment with cefazolin and ceftazidime and in patients who have an increased risk of having enterococci, such as in microbial transmural migration from the gastrointestinal tract, vancomycin should be considered to cover the Gram-positive spectrum, including enterococci (e.g., those with chronic, recurrent diverticulitis).</p><p>Still, other empiric antibiotic therapies are possible, often combining vancomycin for Gram-positive coverage with ceftazidime or gentamicin for Gram-negative coverage [<xref rid="B4-idr-17-00049" ref-type="bibr">4</xref>]. Specifically, if daily IP treatment is not an option, then vancomycin administered IP every other day in combination with oral ciprofloxacin may be considered.</p><p>However, the systematic use of vancomycin in our center is not considered since there is a risk of over- and underdosing that may affect outcome and residual renal function [<xref rid="B27-idr-17-00049" ref-type="bibr">27</xref>,<xref rid="B28-idr-17-00049" ref-type="bibr">28</xref>]. This is of particular relevance as in our outpatient setting, vancomycin level tests are not available on a daily result basis.</p><p>This observational study is part of a quality improvement program and so used routinely collected health data extracted from medical records. As a limitation, not all incidents were described in similar detail and there were data missing for 22 peritonitis episodes, and pathogen identification was missing for some patients who underwent treatment in outside hospitals. Accordingly, this study is not intended to provide transferrable clinical value; rather, it was meant to resolve systematic uncertainty regarding our outpatient resistance profiles and to address the empiric selection of calculated therapy at our center. However, the percentage of culture-negative episodes was just 8% (including those from hospitalized patients), suggesting good overall diagnostic standards. Still, the number of patients and peritonitis episodes was limited, which makes the study more descriptive and less informative on a statistical level, specifically regarding the power of the regression analyses performed for trend analyses and regarding widened confidence intervals observed at the beginning and end of the study period which reflect known edge effects in longitudinal modeling. The model&#x02019;s trend estimates rely on borrowing information from adjacent time points; at the dataset boundaries, the absence of neighbors on one side limits this capability, leading to reduced statistical power and increased estimation uncertainty reflected by greater variance estimates. Our study is retrospective by design and thus limited to the reported outcome measures. Despite these issues, the datasets were sufficient to enable a comprehensive analysis to systematically define the range of infecting organisms causing PD-associated peritonitis and their corresponding antimicrobial resistances.</p><p>Variations in pathogen spectra, as we see in our population in comparison to other centers, can result from regional differences, patient-specific factors (such as lifestyle, education, and pet ownership), patient training, center quality standards, and the proportion of inpatient vs. outpatient-acquired peritonitis [<xref rid="B29-idr-17-00049" ref-type="bibr">29</xref>]. Such factors can change; therefore, continued microbiological surveillance and systematic analysis of resistance profiles are justified.</p><p>Since antibiotic resistance is currently not a systematic issue and given that the center-specific peritonitis rate has declined, a change in our choice of initial therapy is not currently warranted. If continued, monitoring shows different resistances emerging, then this will need to be addressed. Looking ahead, our data also highlight the importance of careful patient selection for PD to ensure a favorable balance between the benefits of the modality and the risk of peritonitis.</p></sec><sec sec-type="conclusions" id="sec5-idr-17-00049"><title>5. Conclusions</title><p>The spectrum of bacterial pathogens found in peritonitis patients undergoing PD and the respective antibiotic resistance patterns of these bacteria were analyzed and systematically described for an outpatient, northeastern German dialysis center, acknowledging the shortcomings of the study design. One case of multi-resistant <italic toggle="yes">Staphylococcus epidermidis</italic> and one multi-resistant Gram-negative pathogen were identified. Considering the identified Gram-positive spectrum and recognizing the potential side effects of vancomycin, cefepime remains a viable choice of initial therapy for most patients at presentation. When enterococci are strongly suspected or when no clinical and laboratory improvements are seen, the treatment regimen should be changed appropriately.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors sincerely acknowledge our centers PD team for their time and effort providing continued patient support and for the constructive feedback drafting this manuscript. </p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-idr-17-00049"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/idr17030049/s1">https://www.mdpi.com/article/10.3390/idr17030049/s1</uri>, Supplementary Material S1: RECORD-checklist; Table S1: Yearly sampling of microorganism, Table S2: Peritonitis associated modality drop out; Figure S1: Sampled etiology spectrum 2015&#x02013;2022, Figure S2: Merged illustration of manuscript <xref rid="idr-17-00049-f003" ref-type="fig">Figure 3</xref>a,b, Figure S3: Alternative trend modelling.</p><supplementary-material id="idr-17-00049-s001" position="float" content-type="local-data"><media xlink:href="idr-17-00049-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, R.P.W. and C.A.; Data curation, A.A. and C.A.; Formal analysis, A.A., S.R., and C.A.; Funding acquisition, R.P.W. and R.C.B.-D.; Investigation, A.A., S.R., P.S., R.P.W., and C.A.; Methodology, A.A., S.R., and C.A.; Project administration, C.A.; Resources, R.P.W. and R.C.B.-D.; Supervision, C.A.; Visualization, C.A.; Writing&#x02014;original draft, A.A., L.C.C.-B., and C.A.; Writing&#x02014;review and editing, A.A., S.R., L.C.C.-B., P.S., R.P.W., R.C.B.-D., and C.A. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board of Diaverum and the Otto-von-Guericke University Medical Faculty Ethics Committee, Magdeburg, Germany, Case No. 142/22 (approved on 21 November 2022).</p></notes><notes><title>Informed Consent Statement</title><p>The requirement for patient consent was waived by the institutional review board due to the retrospective design of the study.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The datasets generated and/or analyzed during the current study are not publicly available due to restrictions specified in the study protocol but are available from the corresponding author on reasonable request.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no potential conflicts of interest with respect to the research, authorship and/or publication of this article.</p></notes><glossary><title>List of Abbreviations</title><p>The following abbreviations are used in this manuscript:
<array><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">APD</td><td align="left" valign="middle" rowspan="1" colspan="1">Automated peritoneal dialysis</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CAPD</td><td align="left" valign="middle" rowspan="1" colspan="1">Continuous ambulatory peritoneal dialysis</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ISPD</td><td align="left" valign="middle" rowspan="1" colspan="1">International Society for Peritoneal Dialysis</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IP</td><td align="left" valign="middle" rowspan="1" colspan="1">Intraperitoneal</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MRSA</td><td align="left" valign="middle" rowspan="1" colspan="1">Methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MRSE</td><td align="left" valign="middle" rowspan="1" colspan="1">Methicillin-resistant <italic toggle="yes">Staphylococcus epidermidis</italic></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MRGN</td><td align="left" valign="middle" rowspan="1" colspan="1">Multi-resistant Gram-negative pathogens</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PD</td><td align="left" valign="middle" rowspan="1" colspan="1">Peritoneal dialysis</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">spp.</td><td align="left" valign="middle" rowspan="1" colspan="1">Species</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">VRE</td><td align="left" valign="middle" rowspan="1" colspan="1">Vancomycin-resistant enterococci</td></tr></tbody></array></p></glossary><ref-list><title>References</title><ref id="B1-idr-17-00049"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Robinski</surname><given-names>M.</given-names></name>
<name><surname>Mau</surname><given-names>W.</given-names></name>
<name><surname>Wienke</surname><given-names>A.</given-names></name>
<name><surname>Girndt</surname><given-names>M.</given-names></name>
</person-group><article-title>The Choice of Renal Replacement Therapy (CORETH) Project: Dialysis Patients&#x02019; Psychosocial Characteristics and Treatment Satisfaction</article-title><source>Nephrol. Dial. Transpl.</source><year>2017</year><volume>32</volume><fpage>315</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfv464</pub-id></element-citation></ref><ref id="B2-idr-17-00049"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Albert</surname><given-names>A.</given-names></name>
<name><surname>Richter</surname><given-names>S.</given-names></name>
<name><surname>Kalk</surname><given-names>P.</given-names></name>
<name><surname>Stieger</surname><given-names>P.</given-names></name>
<name><surname>Woitas</surname><given-names>R.P.</given-names></name>
<name><surname>Braun-Dullaeus</surname><given-names>R.C.</given-names></name>
<name><surname>Albert</surname><given-names>C.</given-names></name>
</person-group><article-title>Analysis of a Nurse-Provided on-Call Peritoneal Dialysis Support in an Outpatient Reference Care Centre</article-title><source>BMC Nurs.</source><year>2024</year><volume>23</volume><elocation-id>144</elocation-id><pub-id pub-id-type="doi">10.1186/s12912-024-01812-4</pub-id><pub-id pub-id-type="pmid">38429782</pub-id>
</element-citation></ref><ref id="B3-idr-17-00049"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Albert</surname><given-names>A.</given-names></name>
<name><surname>Richter</surname><given-names>S.</given-names></name>
<name><surname>Woitas</surname><given-names>R.P.</given-names></name>
<name><surname>Hinkel</surname><given-names>U.P.</given-names></name>
<name><surname>Stieger</surname><given-names>P.</given-names></name>
<name><surname>Braun-Dullaeus</surname><given-names>R.C.</given-names></name>
<name><surname>Albert</surname><given-names>C.</given-names></name>
</person-group><article-title>Baxter Physioneal, Extraneal, Nutrineal (PEN) and Dianeal Solution Bags Can Be Accidentally Connected to Fresenius Peritoneal Dialysis Catheter Extensions in a Non-Sterile Manner</article-title><source>Clin. Kidney J.</source><year>2024</year><volume>17</volume><fpage>sfae067</fpage><pub-id pub-id-type="doi">10.1093/ckj/sfae067</pub-id><pub-id pub-id-type="pmid">38618491</pub-id>
</element-citation></ref><ref id="B4-idr-17-00049"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>P.K.-T.</given-names></name>
<name><surname>Chow</surname><given-names>K.M.</given-names></name>
<name><surname>Cho</surname><given-names>Y.</given-names></name>
<name><surname>Fan</surname><given-names>S.</given-names></name>
<name><surname>Figueiredo</surname><given-names>A.E.</given-names></name>
<name><surname>Harris</surname><given-names>T.</given-names></name>
<name><surname>Kanjanabuch</surname><given-names>T.</given-names></name>
<name><surname>Kim</surname><given-names>Y.-L.</given-names></name>
<name><surname>Madero</surname><given-names>M.</given-names></name>
<name><surname>Malyszko</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>ISPD Peritonitis Guideline Recommendations: 2022 Update on Prevention and Treatment</article-title><source>Periton Dialysis Int.</source><year>2022</year><volume>42</volume><fpage>110</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1177/08968608221080586</pub-id><pub-id pub-id-type="pmid">35264029</pub-id>
</element-citation></ref><ref id="B5-idr-17-00049"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dellit</surname><given-names>T.H.</given-names></name>
<name><surname>Owens</surname><given-names>R.C.</given-names></name>
<name><surname>McGowan</surname><given-names>J.E.</given-names></name>
<name><surname>Gerding</surname><given-names>D.N.</given-names></name>
<name><surname>Weinstein</surname><given-names>R.A.</given-names></name>
<name><surname>Burke</surname><given-names>J.P.</given-names></name>
<name><surname>Huskins</surname><given-names>W.C.</given-names></name>
<name><surname>Paterson</surname><given-names>D.L.</given-names></name>
<name><surname>Fishman</surname><given-names>N.O.</given-names></name>
<name><surname>Carpenter</surname><given-names>C.F.</given-names></name>
<etal/>
</person-group><article-title>Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America Guidelines for Developing an Institutional Program to Enhance Antimicrobial Stewardship</article-title><source>Clin. Infect. Dis.</source><year>2007</year><volume>44</volume><fpage>159</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1086/510393</pub-id><pub-id pub-id-type="pmid">17173212</pub-id>
</element-citation></ref><ref id="B6-idr-17-00049"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Marshall</surname><given-names>M.</given-names></name>
<name><surname>Waters</surname><given-names>G.P.</given-names></name>
<name><surname>Verger</surname><given-names>C.</given-names></name>
</person-group><article-title>Peritoneal Dialysis Associated Peritonitis Rate&#x02014;Validation of a Simplified Formula</article-title><source>Bull. Dial. Domic.</source><year>2021</year><volume>4</volume><fpage>245</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.25796/bdd.v4i4.63443</pub-id></element-citation></ref><ref id="B7-idr-17-00049"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Benchimol</surname><given-names>E.I.</given-names></name>
<name><surname>Smeeth</surname><given-names>L.</given-names></name>
<name><surname>Guttmann</surname><given-names>A.</given-names></name>
<name><surname>Harron</surname><given-names>K.</given-names></name>
<name><surname>Moher</surname><given-names>D.</given-names></name>
<name><surname>Petersen</surname><given-names>I.</given-names></name>
<name><surname>S&#x000f8;rensen</surname><given-names>H.T.</given-names></name>
<name><surname>von Elm</surname><given-names>E.</given-names></name>
<name><surname>Langan</surname><given-names>S.M.</given-names></name>
<name><surname>Committee</surname><given-names>R.W.</given-names></name>
</person-group><article-title>The REporting of Studies Conducted Using Observational Routinely-Collected Health Data (RECORD) Statement</article-title><source>PloS Med.</source><year>2015</year><volume>12</volume><elocation-id>e1001885</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pmed.1001885</pub-id><pub-id pub-id-type="pmid">26440803</pub-id>
</element-citation></ref><ref id="B8-idr-17-00049"><label>8.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>The R Development Core Team</collab>
</person-group><source>R: A Language and Environment for Statistical Computing</source><publisher-name>R Foundation for Statistical Computing</publisher-name><publisher-loc>Vienna, Austria</publisher-loc><year>2023</year></element-citation></ref><ref id="B9-idr-17-00049"><label>9.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Venables</surname><given-names>W.N.</given-names></name>
<name><surname>Ripley</surname><given-names>B.D.</given-names></name>
</person-group><source>Modern Applied Statistics with S</source><edition>4th ed.</edition><publisher-name>Springer</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>2002</year><isbn>0-387-95457-0</isbn></element-citation></ref><ref id="B10-idr-17-00049"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Eckmann</surname><given-names>C.</given-names></name>
<name><surname>Isenmann</surname><given-names>R.</given-names></name>
<name><surname>Kujath</surname><given-names>P.</given-names></name>
<name><surname>Pross</surname><given-names>A.</given-names></name>
<name><surname>Rodloff</surname><given-names>A.C.</given-names></name>
<name><surname>Schmitz</surname><given-names>F.-J.</given-names></name>
</person-group><article-title>Calculated Parenteral Initial Treatment of Bacterial Infections: Intra-Abdominal Infections</article-title><source>GMS Infect. Dis.</source><year>2020</year><volume>8</volume><fpage>Doc13</fpage><pub-id pub-id-type="doi">10.3205/id000057</pub-id><pub-id pub-id-type="pmid">32373438</pub-id>
</element-citation></ref><ref id="B11-idr-17-00049"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Garc&#x000ed;a-Solache</surname><given-names>M.</given-names></name>
<name><surname>Rice</surname><given-names>L.B.</given-names></name>
</person-group><article-title>The Enterococcus: A Model of Adaptability to Its Environment</article-title><source>Clin. Microbiol. Rev.</source><year>2019</year><volume>32</volume><fpage>e00058-18</fpage><pub-id pub-id-type="doi">10.1128/CMR.00058-18</pub-id><pub-id pub-id-type="pmid">30700430</pub-id>
</element-citation></ref><ref id="B12-idr-17-00049"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kitterer</surname><given-names>D.</given-names></name>
<name><surname>Latus</surname><given-names>J.</given-names></name>
<name><surname>P&#x000f6;hlmann</surname><given-names>C.</given-names></name>
<name><surname>Alscher</surname><given-names>M.D.</given-names></name>
<name><surname>Kimmel</surname><given-names>M.</given-names></name>
</person-group><article-title>Microbiological Surveillance of Peritoneal Dialysis Associated Peritonitis: Antimicrobial Susceptibility Profiles of a Referral Center in GERMANY over 32 Years</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><elocation-id>e0135969</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0135969</pub-id><pub-id pub-id-type="pmid">26405797</pub-id>
</element-citation></ref><ref id="B13-idr-17-00049"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Piraino</surname><given-names>B.</given-names></name>
<name><surname>Bernardini</surname><given-names>J.</given-names></name>
<name><surname>Brown</surname><given-names>E.</given-names></name>
<name><surname>Figueiredo</surname><given-names>A.</given-names></name>
<name><surname>Johnson</surname><given-names>D.W.</given-names></name>
<name><surname>Lye</surname><given-names>W.-C.</given-names></name>
<name><surname>Price</surname><given-names>V.</given-names></name>
<name><surname>Ramalakshmi</surname><given-names>S.</given-names></name>
<name><surname>Szeto</surname><given-names>C.-C.</given-names></name>
</person-group><article-title>ISPD Position Statement on Reducing the Risks of Peritoneal Dialysis&#x02013;Related Infections</article-title><source>Perit. Dial. Int.</source><year>2011</year><volume>31</volume><fpage>614</fpage><lpage>630</lpage><pub-id pub-id-type="doi">10.3747/pdi.2011.00057</pub-id><pub-id pub-id-type="pmid">21880990</pub-id>
</element-citation></ref><ref id="B14-idr-17-00049"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kofteridis</surname><given-names>D.P.</given-names></name>
<name><surname>Valachis</surname><given-names>A.</given-names></name>
<name><surname>Perakis</surname><given-names>K.</given-names></name>
<name><surname>Maraki</surname><given-names>S.</given-names></name>
<name><surname>Daphnis</surname><given-names>E.</given-names></name>
<name><surname>Samonis</surname><given-names>G.</given-names></name>
</person-group><article-title>Peritoneal Dialysis-Associated Peritonitis: Clinical Features and Predictors of Outcome</article-title><source>Int. J. Infect. Dis.</source><year>2010</year><volume>14</volume><fpage>e489</fpage><lpage>e493</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2009.07.016</pub-id><pub-id pub-id-type="pmid">19926324</pub-id>
</element-citation></ref><ref id="B15-idr-17-00049"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>van Esch</surname><given-names>S.</given-names></name>
<name><surname>Krediet</surname><given-names>R.T.</given-names></name>
<name><surname>Struijk</surname><given-names>D.G.</given-names></name>
</person-group><article-title>32 Years&#x02019; Experience of Peritoneal Dialysis-Related Peritonitis in a University Hospital</article-title><source>Periton Dialysis Int.</source><year>2014</year><volume>34</volume><fpage>162</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.3747/pdi.2013.00275</pub-id></element-citation></ref><ref id="B16-idr-17-00049"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zeng</surname><given-names>Y.</given-names></name>
<name><surname>Jiang</surname><given-names>L.</given-names></name>
<name><surname>Lu</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Song</surname><given-names>K.</given-names></name>
<name><surname>Shen</surname><given-names>H.</given-names></name>
<name><surname>Feng</surname><given-names>S.</given-names></name>
</person-group><article-title>Peritoneal Dialysis-Related Peritonitis Caused by Gram-Negative Organisms: Ten-Years Experience in a Single Center</article-title><source>Ren. Fail.</source><year>2021</year><volume>43</volume><fpage>993</fpage><lpage>1003</lpage><pub-id pub-id-type="doi">10.1080/0886022X.2021.1939050</pub-id><pub-id pub-id-type="pmid">34157941</pub-id>
</element-citation></ref><ref id="B17-idr-17-00049"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>dos Santos</surname><given-names>A.C.M.L.</given-names></name>
<name><surname>Hernandes</surname><given-names>R.T.</given-names></name>
<name><surname>Montelli</surname><given-names>A.C.</given-names></name>
<name><surname>Monteiro</surname><given-names>A.C.M.</given-names></name>
<name><surname>Barbosa</surname><given-names>T.A.</given-names></name>
<name><surname>Camargo</surname><given-names>C.H.</given-names></name>
<name><surname>Ferreira</surname><given-names>A.M.</given-names></name>
<name><surname>Mondelli</surname><given-names>A.L.</given-names></name>
<name><surname>de Lourdes Ribeiro de Souza da Cunha</surname><given-names>M.</given-names></name>
<name><surname>Barretti</surname><given-names>P.</given-names></name>
</person-group><article-title>Clinical and Microbiological Factors Predicting Outcomes of Nonfermenting Gram-Negative Bacilli Peritonitis in Peritoneal Dialysis</article-title><source>Sci. Rep.</source><year>2021</year><volume>11</volume><fpage>12248</fpage><pub-id pub-id-type="doi">10.1038/s41598-021-91410-0</pub-id><pub-id pub-id-type="pmid">34112833</pub-id>
</element-citation></ref><ref id="B18-idr-17-00049"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bunke</surname><given-names>C.M.</given-names></name>
<name><surname>Brier</surname><given-names>M.E.</given-names></name>
<name><surname>Golper</surname><given-names>T.A.</given-names></name>
</person-group><article-title>Outcomes of Single Organism Peritonitis in Peritoneal Dialysis: Gram Negatives versus Gram Positives in the Network 9 Peritonitis Study</article-title><source>Kidney Int.</source><year>1997</year><volume>52</volume><fpage>524</fpage><lpage>529</lpage><pub-id pub-id-type="doi">10.1038/ki.1997.363</pub-id><pub-id pub-id-type="pmid">9264012</pub-id>
</element-citation></ref><ref id="B19-idr-17-00049"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sanchez</surname><given-names>A.R.</given-names></name>
<name><surname>Madonia</surname><given-names>C.</given-names></name>
<name><surname>Rascon-Pacheco</surname><given-names>R.A.</given-names></name>
</person-group><article-title>Improved Patient/Technique Survival and Peritonitis Rates in Patients Treated with Automated Peritoneal Dialysis When Compared to Continuous Ambulatory Peritoneal Dialysis in a Mexican PD Center</article-title><source>Kidney Int.</source><year>2008</year><volume>73</volume><fpage>S76</fpage><lpage>S80</lpage><pub-id pub-id-type="doi">10.1038/sj.ki.5002606</pub-id><pub-id pub-id-type="pmid">18379553</pub-id>
</element-citation></ref><ref id="B20-idr-17-00049"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kokubu</surname><given-names>M.</given-names></name>
<name><surname>Matsui</surname><given-names>M.</given-names></name>
<name><surname>Uemura</surname><given-names>T.</given-names></name>
<name><surname>Morimoto</surname><given-names>K.</given-names></name>
<name><surname>Eriguchi</surname><given-names>M.</given-names></name>
<name><surname>Samejima</surname><given-names>K.</given-names></name>
<name><surname>Akai</surname><given-names>Y.</given-names></name>
<name><surname>Tsuruya</surname><given-names>K.</given-names></name>
</person-group><article-title>Relationship between Initial Peritoneal Dialysis Modality and Risk of Peritonitis</article-title><source>Sci. Rep.</source><year>2020</year><volume>10</volume><fpage>18763</fpage><pub-id pub-id-type="doi">10.1038/s41598-020-75918-5</pub-id><pub-id pub-id-type="pmid">33127929</pub-id>
</element-citation></ref><ref id="B21-idr-17-00049"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wong</surname><given-names>P.-N.</given-names></name>
<name><surname>Lo</surname><given-names>K.-Y.</given-names></name>
<name><surname>Tong</surname><given-names>G.M.W.</given-names></name>
<name><surname>Chan</surname><given-names>S.-F.</given-names></name>
<name><surname>Lo</surname><given-names>M.-W.</given-names></name>
<name><surname>Mak</surname><given-names>S.-K.</given-names></name>
<name><surname>Wong</surname><given-names>A.K.M.</given-names></name>
</person-group><article-title>Prevention of Fungal Peritonitis with Nystatin Prophylaxis in Patients Receiving CAPD</article-title><source>Perit. Dial. Int. J. Int. Soc. Perit. Dial.</source><year>2007</year><volume>27</volume><fpage>531</fpage><lpage>536</lpage><pub-id pub-id-type="doi">10.1177/089686080702700512</pub-id></element-citation></ref><ref id="B22-idr-17-00049"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kitrungphaiboon</surname><given-names>T.</given-names></name>
<name><surname>Puapatanakul</surname><given-names>P.</given-names></name>
<name><surname>Chuengsaman</surname><given-names>P.</given-names></name>
<name><surname>Tiskajornsiri</surname><given-names>K.</given-names></name>
<name><surname>Halue</surname><given-names>G.</given-names></name>
<name><surname>Siribamrungwong</surname><given-names>M.</given-names></name>
<name><surname>Matayart</surname><given-names>S.</given-names></name>
<name><surname>Chongthanakorn</surname><given-names>K.</given-names></name>
<name><surname>Poonvivatchaikarn</surname><given-names>U.</given-names></name>
<name><surname>Boonyakrai</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Intraperitoneal Cefepime Monotherapy Versus Combination Therapy of Cefazolin Plus Ceftazidime for Empirical Treatment of CAPD-Associated Peritonitis: A Multicenter, Open-Label, Noninferiority, Randomized, Controlled Trial</article-title><source>Am. J. Kidney Dis.</source><year>2019</year><volume>74</volume><fpage>601</fpage><lpage>609</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2019.05.011</pub-id><pub-id pub-id-type="pmid">31331757</pub-id>
</element-citation></ref><ref id="B23-idr-17-00049"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yahav</surname><given-names>D.</given-names></name>
<name><surname>Paul</surname><given-names>M.</given-names></name>
<name><surname>Fraser</surname><given-names>A.</given-names></name>
<name><surname>Sarid</surname><given-names>N.</given-names></name>
<name><surname>Leibovici</surname><given-names>L.</given-names></name>
</person-group><article-title>Efficacy and Safety of Cefepime: A Systematic Review and Meta-Analysis</article-title><source>Lancet Infect. Dis.</source><year>2007</year><volume>7</volume><fpage>338</fpage><lpage>348</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(07)70109-3</pub-id><pub-id pub-id-type="pmid">17448937</pub-id>
</element-citation></ref><ref id="B24-idr-17-00049"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>So</surname><given-names>S.W.Y.</given-names></name>
<name><surname>Chen</surname><given-names>L.</given-names></name>
<name><surname>Woo</surname><given-names>A.Y.H.</given-names></name>
<name><surname>Ng</surname><given-names>D.M.H.</given-names></name>
<name><surname>Wong</surname><given-names>J.K.W.</given-names></name>
<name><surname>Chow</surname><given-names>K.M.</given-names></name>
<name><surname>Runnegar</surname><given-names>N.</given-names></name>
<name><surname>Johnson</surname><given-names>D.W.</given-names></name>
<name><surname>Li</surname><given-names>P.K.-T.</given-names></name>
</person-group><article-title>Stability and Compatibility of Antibiotics in Peritoneal Dialysis Solutions</article-title><source>Clin. Kidney J.</source><year>2022</year><volume>15</volume><fpage>1071</fpage><lpage>1078</lpage><pub-id pub-id-type="doi">10.1093/ckj/sfac012</pub-id><pub-id pub-id-type="pmid">35664278</pub-id>
</element-citation></ref><ref id="B25-idr-17-00049"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Peng</surname><given-names>Q.</given-names></name>
<name><surname>Tang</surname><given-names>X.</given-names></name>
<name><surname>Dong</surname><given-names>W.</given-names></name>
<name><surname>Sun</surname><given-names>N.</given-names></name>
<name><surname>Yuan</surname><given-names>W.</given-names></name>
</person-group><article-title>A Review of Biofilm Formation of <italic toggle="yes">Staphylococcus aureus</italic> and Its Regulation Mechanism</article-title><source>Antibiotics</source><year>2022</year><volume>12</volume><elocation-id>12</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics12010012</pub-id><pub-id pub-id-type="pmid">36671212</pub-id>
</element-citation></ref><ref id="B26-idr-17-00049"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mahlen</surname><given-names>S.D.</given-names></name>
</person-group><article-title>Serratia Infections: From Military Experiments to Current Practice</article-title><source>Clin. Microbiol. Rev.</source><year>2011</year><volume>24</volume><fpage>755</fpage><lpage>791</lpage><pub-id pub-id-type="doi">10.1128/CMR.00017-11</pub-id><pub-id pub-id-type="pmid">21976608</pub-id>
</element-citation></ref><ref id="B27-idr-17-00049"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Deacon</surname><given-names>E.</given-names></name>
<name><surname>Canney</surname><given-names>M.</given-names></name>
<name><surname>McCormick</surname><given-names>B.</given-names></name>
<name><surname>Brown</surname><given-names>P.</given-names></name>
<name><surname>Biyani</surname><given-names>M.</given-names></name>
<name><surname>Zimmerman</surname><given-names>D.</given-names></name>
</person-group><article-title>Predictors of Serum Vancomycin Levels in Peritoneal Dialysis-Associated Peritonitis</article-title><source>Perit. Dial. Int.</source><year>2023</year><volume>43</volume><fpage>45</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1177/08968608221134980</pub-id><pub-id pub-id-type="pmid">36350011</pub-id>
</element-citation></ref><ref id="B28-idr-17-00049"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Deacon</surname><given-names>E.</given-names></name>
<name><surname>Canney</surname><given-names>M.</given-names></name>
<name><surname>McCormick</surname><given-names>B.</given-names></name>
<name><surname>Ramsay</surname><given-names>T.</given-names></name>
<name><surname>Biyani</surname><given-names>M.</given-names></name>
<name><surname>Brown</surname><given-names>P.A.</given-names></name>
<name><surname>Zimmerman</surname><given-names>D.</given-names></name>
</person-group><article-title>The Association Between Serum Vancomycin Level and Clinical Outcome in Patients With Peritoneal Dialysis Associated Peritonitis</article-title><source>Kidney Int. Rep.</source><year>2023</year><volume>8</volume><fpage>2646</fpage><lpage>2653</lpage><pub-id pub-id-type="doi">10.1016/j.ekir.2023.09.013</pub-id><pub-id pub-id-type="pmid">38106569</pub-id>
</element-citation></ref><ref id="B29-idr-17-00049"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>You</surname><given-names>L.</given-names></name>
<name><surname>Zhang</surname><given-names>B.</given-names></name>
<name><surname>Zhang</surname><given-names>F.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
</person-group><article-title>Pathogenic Spectrum and Risk Factors of Peritoneal Dialysis-Associated Peritonitis: A Single-Center Retrospective Study</article-title><source>BMC Infect. Dis.</source><year>2024</year><volume>24</volume><elocation-id>440</elocation-id><pub-id pub-id-type="doi">10.1186/s12879-024-09334-9</pub-id><pub-id pub-id-type="pmid">38658811</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="idr-17-00049-f001"><label>Figure 1</label><caption><p>Assessed number of PD patients, peritonitis episodes, and the corresponding peritonitis rate over time. As suggested by the ISPD in 2022, the overall peritonitis rate should be no more than 0.40 (down from 0.5 before that).</p></caption><graphic xlink:href="idr-17-00049-g001" position="float"/></fig><fig position="float" id="idr-17-00049-f002"><label>Figure 2</label><caption><p>Overview of the pathogenic spectrum found each year over the 2015&#x02013;2022 period, N = 98.</p></caption><graphic xlink:href="idr-17-00049-g002" position="float"/></fig><fig position="float" id="idr-17-00049-f003"><label>Figure 3</label><caption><p>(<bold>a</bold>) Locally Estimated Scatterplot Smoothing (LOESS) was applied to local polynomial regressions to model detection rate trends in microorganism categories over time to provide a visual estimate of non-linear trends. (<bold>b</bold>) Microorganism detection rates per year with linear trend estimates, calculated using ordinary least-squares regression (OLS) with 95% confidence intervals.</p></caption><graphic xlink:href="idr-17-00049-g003" position="float"/></fig><table-wrap position="float" id="idr-17-00049-t001"><object-id pub-id-type="pii">idr-17-00049-t001_Table 1</object-id><label>Table 1</label><caption><p>Demographic and Clinical Characteristics of Patients and Peritonitis Episodes.</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Total PD patients during timeframe, N</td><td align="left" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">129</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Most recent PD modality (APD:CAPD:IPD)</td><td align="left" valign="middle" rowspan="1" colspan="1">79:39:11</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Sex (Male; Female)</td><td align="left" valign="middle" rowspan="1" colspan="1">82; 47</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Age at PD initiation, Median (25&#x02013;75 CI), years</td><td align="left" valign="middle" rowspan="1" colspan="1">69 (55&#x02013;78)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Age at first peritonitis episode, Median (25&#x02013;75 CI), years</td><td align="left" valign="middle" rowspan="1" colspan="1">73 (62&#x02013;79)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Time from PD initiation to first peritonitis episode, Median (25&#x02013;75 CI), months</td><td align="left" valign="middle" rowspan="1" colspan="1">13 (4&#x02013;24)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Relapsing peritonits, N (%)</td><td align="left" valign="middle" rowspan="1" colspan="1">3 (3.75)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Recurrent peritonitis, N (%)</td><td align="left" valign="middle" rowspan="1" colspan="1">3 (3.75)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Repeat peritonits, N (%)</td><td align="left" valign="middle" rowspan="1" colspan="1">8 (10.0)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Tunnel affection, N (%)</td><td align="left" valign="middle" rowspan="1" colspan="1">6 (7.5)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Peritonitis associated modality switch, N (%) *</td><td align="left" valign="middle" rowspan="1" colspan="1">14 (17.5)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Died in hospital related to peritonitis, N (%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (2.5)</td></tr></tbody></table><table-wrap-foot><fn><p>PD = peritoneal dialysis; APD = automated peritoneal dialysis; CAPD = continuous ambulatory peritoneal dialysis; IPD = intermittent peritoneal dialysis (performed in center). Numbers denote Median (1st&#x02013;3rd quartile) or N (%) as appropriate. * Combined temporal and permanent.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="idr-17-00049-t002"><object-id pub-id-type="pii">idr-17-00049-t002_Table 2</object-id><label>Table 2</label><caption><p>Etiology of microorganism regarding the peritonitis episodes from 2015 till 2022.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Microorganism</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">N (%)</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Family</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Potential Origin</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gram-Positives</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">56 (56.57)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Staphylococcus aureus</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">14 (14.14)</td><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Staphylococcaceae</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">upper respiratory tract and skin microbiota</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Staphylococcus epidermidis</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (7.07)</td><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Staphylococcaceae</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">typically skin microbiota, less commonly the mucosal microbiota</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Staphylococcus haemolyticus</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (6.06)</td><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Staphylococcaceae</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">skin microbiota</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Enterococcus faecialis</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (4.04)</td><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Enterococcaceae</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">physiologic gastrointestinal tracts microbiota</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Streptococcus mitis</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (4.04)</td><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Streptococcaceae</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">human mouth, throat, and upper respiratory tract microbiota</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Coagulase negative Staphylococci</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (2.02)</td><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Staphylococcaceae</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">physiologic skin flora</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Staphylococcus capitis</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (2.02)</td><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Staphylococcaceae</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">skin and nasal microbiota</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Streptococcus agalacitae</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (2.02)</td><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Streptococcaceae</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">gastrointestinal and genitourinary tract microbiota</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Streptococcus dysgalactiae</italic> ssp. <italic toggle="yes">equisimilis</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (2.02)</td><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Streptococcaceae</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">gastroinetstinal and genital tract, less commonly the skin flora. </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Streptococcus salivarius</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (2.02)</td><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Streptococcaceae</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">the oral cavity and upper respiratory tract</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Actinomyces neuii</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (1.01)</td><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Actinomycetaceae</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">vaginal microbiota</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Bacillus cereus</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (1.01)</td><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Bacillaceae</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">found in earth and soil</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Brevibacterium casei</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (1.01)</td><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Brevibacteriaceae</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">raw milk and cheese manufacturing</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Coyrnebacterium</italic> spp.
</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (1.01)</td><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Corynebacteriaceae</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">upper respiratory tract and skin microbiota</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Enterococcus</italic> spp.
</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (1.01)</td><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Enterococcaceae</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">gastrointestinal and genitourinary tract microbiota</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Listeria monozytogenes</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (1.01)</td><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Listeriaceae</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">gastrointestinal, contaminated drinking water or food</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Micrococcus luteus</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (1.01)</td><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Micrococcaceae</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">found in soil, dust, water and air, and as part of the microbiota of the mammalian skin</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Norcadia</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (1.01)</td><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Nocardiaceae</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">oral microflora </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Staphylococcus hominis</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (1.01)</td><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Staphylococcaceae</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">human and animal skin</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Streptococcus pneumoniae</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (1.01)</td><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Streptococcaceae</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">respiratory tract, sinuses, and nasal cavity</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Streptococcus pyogenes</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (1.01)</td><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Streptococcaceae</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">skin microbiota</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gram-negatives</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">31 (31.31)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Escherichia coli</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">9 (9.09)</td><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Enterobacteriaceae</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">gastrointestinal and genitourinary tract</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Enterobacter cloacae</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (5.05)</td><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Enterobacteriaceae</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">gastrointestinal microbiota</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Klebsiella oxytoca</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (4.04)</td><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Enterobacteriaceae</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">opportunistic and gastrointestinal origin</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Serratia marcescens</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (3.03)</td><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Yersiniaceae</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">ubiquitous in soil, water, animals and plants</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Acinetobacter baumanii</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (2.02)</td><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Moraxellaceae</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">hospital environments; environmental soil and water samples</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Klebsiella pneumoniae</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (3.03)</td><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Enterobacteriaceae</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">mouth, skin, and intestinal microbiota</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Acinetobacter pittii</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (1.01)</td><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Moraxellaceae</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">skin and upper respiratory tract</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Bacteroides uniforms</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (1.01)</td><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Bacteroidaceae</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">lower intestinal tract microbiota</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Pantonea agglomerans</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (1.01)</td><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Enterobacteriaceae</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">commonly present on plant surfaces and animal or human feces</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Pasteurella multocida</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (1.01)</td><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Pasteurellaceae</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">domestic cats and dogs normal respiratory microbiota</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Raoultella (Klebsiella) planticola</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (1.01)</td><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Enterobacteriaceae</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">ubiquitous, may colonize plants, water, animals and humans</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fungi</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (3.03)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Candida parapsilosis</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (2.02)</td><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Saccharomycetacea</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">hospital environments; catheter surfaces</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Candida</italic> spp.</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (1.01)</td><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Saccharomycetaceae</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">hospital environments; catheter surfaces</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Other</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9 (9.09)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">culture-negative</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (8.08)</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">no data record</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (1.01)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02013;</td></tr></tbody></table></table-wrap></floats-group></article>